Zealand Pharma A/S (OTCMKTS:ZLDPF) Lowered to “Strong Sell” Rating by Zacks Research

Zealand Pharma A/S (OTCMKTS:ZLDPF) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Thursday,Zacks.com reports.

Several other equities analysts have also recently commented on the company. Wolfe Research cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Berenberg Bank downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th. Jefferies Financial Group downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold”.

Zealand Pharma A/S Price Performance

Shares of OTCMKTS:ZLDPF opened at $52.68 on Thursday. The firm has a fifty day moving average price of $45.69 and a two-hundred day moving average price of $49.49. The company has a market cap of $3.77 billion, a price-to-earnings ratio of 8.74 and a beta of 0.88. The company has a debt-to-equity ratio of 0.02, a current ratio of 37.17 and a quick ratio of 37.17. Zealand Pharma A/S has a one year low of $35.93 and a one year high of $83.12.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, August 13th. The company reported $8.61 earnings per share for the quarter, topping the consensus estimate of $0.14 by $8.47. Zealand Pharma A/S had a net margin of 58.86% and a return on equity of 18.53%. The firm had revenue of $698.62 million for the quarter, compared to analysts’ expectations of $692.12 million. Analysts anticipate that Zealand Pharma A/S will post 2.37 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.